Table 2.
Cell viability measurements of curcumin (C), C-150, and bortezomib (BTZ) alone and in combination with CellTiter-Glo assay. Curcumin and its analogue C-150 significantly potentiated the effect of bortezomib (P 1: bortezomib versus combination; P 2: curcumin or C-150 versus combination; two-tailed Student's t-test).
| — | BTZ (50 nM) |
BTZ (12.5 nM) |
BTZ (3.125 nM) |
BTZ (0.78 nM) |
|
|---|---|---|---|---|---|
| — | 0.11 | 0.16 | 0.91 | 0.94 | |
| C (50 µM) | 0.12 | 0.11 | 0.12 | 0.12 | 0.11 |
| C (25 µM) | 0.17 | 0.15 | 0.13 |
0.13
(P 1 < 0.01, P 2 < 0.05) |
0.13
(P 1 < 0.01, P 2 < 0.05) |
| C (10 µM) | 0.99 | 0.11 | 0.15 | 0.52 (P 1, P 2 < 0.01) |
0.87 |
| C (5 µM) | 1.08 | 0.11 | 0.17 | 0.79 | 1.05 |
| C-150 (1 µM) | 0.09 | 0.10 |
0.10
(P 1 < 0.01, P 2 < 0.05) |
0.08 | 0.08 |
| C-150 (0.5 µM) | 0.16 | 0.10 | 0.10 | 0.12 | 0.16 |
| C-150 (0.1 µM) | 0.99 |
0.08
(P 1 < 0.05, P 2 < 0.01) |
0.12 (P 1 < 0.05, P 2 < 0.01) |
0.58
( P 1, P 2 < 0.01) |
0.90 |
| C-150 (0.05 µM) | 0.93 | 0.10 | 0.15 |
0.69
(P 1 < 0.01, P 2 < 0.05) |
1.02 |